Core Insights - Tvardi Therapeutics, Inc. experienced a significant decline in its stock price, dropping over 80% following disappointing preliminary data from its Phase 2 REVERT clinical trial for TTI-101 in idiopathic pulmonary fibrosis [2]. Company Overview - Tvardi Therapeutics, Inc. is currently under investigation by Faruqi & Faruqi, LLP for potential claims related to the substantial losses suffered by investors due to the recent stock price drop [1][3]. Clinical Trial Results - The Phase 2 REVERT clinical trial aimed to evaluate the safety, pharmacokinetics, and exploratory outcomes related to lung function of TTI-101. However, the preliminary data indicated that the study did not meet its goals, particularly in terms of changes in Forced Vital Capacity (FVC) [2]. - The preliminary data showed that the baseline characteristics of patients were similar across treatment arms, except for the percent predicted FVC, which was lower in the placebo group compared to the TTI-101 group [2].

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on October 14, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 59 Front Street Millbrook, NY 12545 Tel.: (646) 387-7129 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 General Purpose Acquisition Corp. (Exact ...

DEADLINE: October 27, 2025 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. LifeMD raised its guidance for fiscal year 2025 while ignoring important factors like customer acquisition costs. Based on these facts, LifeMD's public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate . NEXT STEPS FOR SHAREHOLDERS : Once you register as a shareholder who purchas ...

Core Points - A class action lawsuit has been filed against Dow Inc. for violations of the Securities Exchange Act of 1934, specifically citing false and misleading statements regarding financial pressures and market conditions [1][2] - The class period for the lawsuit is from March 10, 2021, to April 15, 2025, with a deadline for lead plaintiff appointments set for October 29, 2025 [2] Company Details - The lawsuit alleges that Dow Inc. was overly optimistic about its ability to maintain shareholder dividends and did not adequately disclose the financial challenges it was facing [2] - The DJS Law Group, which is handling the case, specializes in securities class actions and corporate governance litigation, representing large hedge funds and asset managers [4]

Core Viewpoint - A class action securities lawsuit has been filed against Charter Communications, Inc. alleging securities fraud affecting investors during a specific time frame [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who purchased or acquired Charter securities or options between July 26, 2024, and July 24, 2025 [2]. - The complaint alleges that the company made false statements regarding the impact of the Affordable Connectivity Program (ACP) ending, which was not managed effectively [3]. - It is claimed that the ACP's end had a significant negative impact on internet customer declines and revenue, which the company failed to address adequately [3]. Group 2: Company Operations and Misrepresentation - The lawsuit asserts that Charter was not executing broader operations effectively to compensate for the negative impacts of the ACP ending [3]. - The decline in internet customers and the company's execution failures posed greater risks to business plans and earnings growth than reported [3]. - The defendants allegedly misled investors by providing overly optimistic statements about the company's operations and long-term growth trajectory [3]. Group 3: Next Steps for Affected Investors - Investors who suffered losses during the relevant time frame have until October 14, 2025, to request appointment as lead plaintiff [4]. - Participation in the lawsuit does not require any out-of-pocket costs for class members [4]. Group 4: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]. - The firm is recognized as one of the top securities litigation firms in the United States [5].

Accessibility StatementSkip Navigation BENSALEM, Pa., Sept. 30, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against RCI Hospitality Holdings, Inc. ("RCI" or the "Company") (NASDAQ:Â RICK). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN RCI HOSPITALITY HOLDINGS, INC. (RICK), CONTACT THE LAW OFFICES OF HOWARD G. SMITHÂ BEFORE NOVEMBER 20, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). Shareholders who purchased shares of LNTH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE:https://securitiesclasslaw.com/securities/lantheus-holdings-inc-loss-submission-f ...

Core Points - The Gross Law Firm has issued a notice to shareholders of PubMatic, Inc. regarding a class action lawsuit due to alleged misleading statements made by the company during a specified class period [1] - The class period for the lawsuit is from February 27, 2025, to August 11, 2025, during which significant issues regarding ad spend and revenue were raised [1][2] - Allegations include that a major demand side platform buyer shifted clients to a new platform, leading to a reduction in revenue for PubMatic, which contradicts the company's positive statements about its business [1] Summary by Sections Allegations - The complaint alleges that PubMatic failed to disclose that a top demand side platform buyer was moving clients to a different platform, which evaluated inventory differently [1] - This shift resulted in a decrease in ad spend and revenue from this buyer, making the company's positive statements misleading [1] Class Action Details - Shareholders who purchased shares during the class period are encouraged to register for the class action, with a deadline of October 20, 2025, to seek lead plaintiff status [2] - Registration allows shareholders to receive updates on the case's progress through portfolio monitoring software [2] Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3]

Core Points - V.F. Corporation is facing a class action securities lawsuit due to alleged securities fraud impacting investors between October 30, 2023, and May 20, 2025 [1] - The lawsuit claims that V.F. Corporation misled investors regarding the turnaround plans for the Vans brand, which experienced a significant decline in revenue growth [2] - Following the release of disappointing fiscal results on May 21, 2025, V.F. Corporation's stock price dropped approximately 15.8% in one day, from $14.43 to $12.15 per share [2] Class Action Details - The lawsuit seeks to recover losses for investors adversely affected by the alleged fraud [1] - Investors have until November 12, 2025, to request to be appointed as lead plaintiff, although participation does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs [3] Company Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, alleging that these companies made materially false and misleading statements regarding their business operations and prospects [1]. Group 1: PubMatic, Inc. (NASDAQ: PUBM) - The class period for PubMatic is from February 27, 2025, to August 11, 2025, with a lead plaintiff deadline of October 20, 2025 [2]. - Allegations include failure to disclose a significant shift of clients to a new platform by a top DSP buyer, resulting in reduced ad spend and revenue for PubMatic [2]. - Defendants' positive statements about the company's business were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Snap Inc. (NYSE: SNAP) - The class period for Snap is from April 29, 2025, to August 5, 2025, with a lead plaintiff deadline of October 20, 2025 [3]. - The complaint alleges that Snap's optimistic reports on advertising growth were misleading, as they relied too heavily on the company's execution capabilities [3]. - Defendants failed to disclose significant execution errors and macroeconomic challenges, leading to materially misleading statements about the company's prospects [3]. Group 3: Nutex Health Inc. (NASDAQ: NUTX) - The class period for Nutex is from August 8, 2024, to August 14, 2025, with a lead plaintiff deadline of October 21, 2025 [4]. - Allegations include engaging in a scheme to defraud insurance companies, leading to unsustainable revenue claims [4]. - The company overstated its ability to remediate internal control weaknesses, resulting in improper accounting of stock-based compensation obligations [4]. Group 4: C3.ai, Inc. (NYSE: AI) - The class period for C3.ai is from February 26, 2025, to August 8, 2025, with a lead plaintiff deadline of October 21, 2025 [6]. - The complaint alleges that the company's optimistic growth reports were misleading, relying heavily on the CEO's health and effectiveness [6]. - Defendants failed to disclose that the CEO had not sufficiently recovered to fulfill his role, leading to materially misleading statements about the company's prospects [6].